Amur Maackia (Maackia amurensis) Seed Lectin History and Potential Effect on Cancer Progression, Inflammation and Viral Infection

Tyler J. Hellmig, Eamonn J. Brace, Amanda Greenspan, Christopher Laugier, Abhay Aradhya, Sayan Basu, Saumil Parikh, Katarzyna Jachimowska, Xiaoxuan Wu, Yongquan Shen, Kelly L. Hamilton, Gary S. Goldberg

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Maackia amurensis seed lectin (MASL) is a natural product with an extensive history in medicine. Lectins such as MASL are unique pharmacologic agents that can survive gastrointestinal digestion. They can target specific sugar moieties on extracellular receptors to affect dynamic signaling pathways. In particular, MASL can bind sialic acid moieties on receptors including PDPN and ACE2 in order to inhibit molecular pathways that drive cancer progression, inflammation, and viral infection. Therefore, MASL is an enticing drug candidate with potential to treat pathologies including cancer, arthritis, psoriasis, and COVID. At the time of this writing, MASL is being studied in a phase 1 clinical trial aimed at oral cancer.

Original languageEnglish (US)
Title of host publicationAncient and Traditional Foods, Plants, Herbs and Spices used in Cancer
PublisherCRC Press
Pages89-102
Number of pages14
ISBN (Electronic)9781000902556
ISBN (Print)9781032192536
DOIs
StatePublished - Jan 1 2023
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Health Professions
  • General Medicine

Fingerprint

Dive into the research topics of 'Amur Maackia (Maackia amurensis) Seed Lectin History and Potential Effect on Cancer Progression, Inflammation and Viral Infection'. Together they form a unique fingerprint.

Cite this